A. Lopez‐Chavez

发表

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

A. Mansfield, T. Mok, Melissa L. Johnson, 2018, The New England journal of medicine.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

G. Giaccone, M. Raffeld, L. Xi, 2011, Oncogene.

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Udayan Guha, Seth M Steinberg, Keith Killian, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2017 .

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF.

J. Siegfried, A. López-Chávez, Cassandra Henry, 2012, Current angiogenesis.

Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.

G. Giaccone, C. Moran, L. Nieman, 2012, The Journal of clinical endocrinology and metabolism.

Association of patient characteristics with chemotherapy receipt among depressed and non‐depressed patients with non‐small cell lung cancer

C. Slatore, A. López-Chávez, L. Ganzini, 2014, Psycho-oncology.

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

G. Giaccone, E. Szabo, J. Trepel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC).

G. Giaccone, Helen X. Chen, A. Rajan, 2010 .

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

G. Giaccone, S. Steinberg, E. Szabo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2018 .

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

M. Socinski, A. Sandler, M. Reck, 2018 .

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

G. Giaccone, S. Steinberg, P. Choyke, 2011, Clinical Cancer Research.

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

D. Citrin, John C. Morris, J. Janik, 2011, Molecular Cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

L. Sequist, Keunchil Park, R. Doebele, 2019, The oncologist.

A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.

L. Sequist, G. MacBeath, Keunchil Park, 2014 .

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

Yi-Song Wang, G. Giaccone, Anish Thomas, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

G. Giaccone, R. Herbst, J. Jassem, 2017 .

Systemic issues in small cell lung cancer.

A. Sandler, A. López-Chávez, A. Lopez‐Chavez, 2012, Current problems in cancer.